Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment

Prostate cancer is the second most common cause of cancer‐related death in men in the United States and the fifth worldwide. Most prostate cancer arises as an androgen‐dependent tumor but eventually progresses into castration‐resistance prostate cancer, incurable by the current androgen deprivation therapy and chemotherapy. The development of immunotherapy in cancer treatment has brought an exciting era of antiprostate cancer therapy through...